A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
2010 ◽
Vol 17
(4)
◽
pp. 880-887
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 4669-4669
2020 ◽
2010 ◽
Vol 103
(4)
◽
pp. 462-468
◽
2011 ◽
Vol 69
(3)
◽
pp. 763-771
◽